Femasys Reports $2.29M Revenue, $(0.47) Net Loss Per Share in 2025 10-K
Summary
Femasys reported its 2025 fiscal year results from its 10-K filing, showing revenue of $2.29 million, a 40.8% increase year-over-year, driven by commercialization of FemBloc and FemaSeed. However, the company posted a significant net loss per share of $(0.47). This follows a Reuters report earlier today that highlighted a 41% sales surge, but the 10-K provides the official figures and, critically, the substantial net loss per share. This loss is particularly impactful given the company's current stock price of $0.425, indicating ongoing operational losses and potential financial strain for the small-cap company. Investors will closely monitor Femasys's ability to reduce these losses and achieve profitability amidst its commercialization efforts and recent corporate governance actions, including a proposed reverse stock split.
At the time of this announcement, FEMY was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25M. The 52-week trading range was $0.31 to $1.34. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.